Skip to search formSkip to main contentSkip to account menu

MBP-8298

Known as: MBP8298 
National Institutes of Health

Related topics

Related topics

3 relations
Dirucotide

Broader (2)

Myelin Basic ProteinsPeptide Fragments

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Effect of different doses of gadolinium contrast agent on clinical outcomes in MS
Objective The objective of this paper is to evaluate potential dose-dependent adverse effects of gadolinium-based contrast agents… 
2008
2008
Dirucotide (MBP8298) for the treatment of multiple sclerosis
Multiple sclerosis (MS) is a chronic and debilitating disease affecting approximately 2.5 million people worldwide, and safe and… 
2006
2006
MBP-8298. Agent for multiple sclerosis
Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating disorder that is estimated to affect about 2.5 million… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)